ICA 110381, also known as Compound 16, is primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders. It functions as a selective modulator of specific ion channels, which play a critical role in regulating neuronal excitability. This makes it a promising candidate for the treatment of conditions such as epilepsy, where abnormal neuronal activity is a key factor. Additionally, its mechanism of action suggests potential utility in managing neuropathic pain, as it may help in stabilizing overactive nerve signals. Research is also exploring its application in mood disorders, including anxiety and depression, due to its ability to influence pathways associated with emotional regulation. Preclinical studies indicate that ICA 110381 could offer a novel approach with fewer side effects compared to existing treatments, making it a focus of ongoing pharmaceutical development.